| Variable |
Linear
(N=47) |
CFAE
(N=45) |
P-value |
| Age (years) |
60.9 |
(8.3) |
60.5 |
(10.2) |
0.85 |
| Gender, n (%) |
|
|
|
|
0.15 |
| . Male |
41 |
(87%) |
34 |
(76%) |
|
| . Female |
6 |
(13%) |
11 |
(24%) |
|
| Body Mass Index |
34.9 |
(6.8) |
34.4 |
(7.8) |
0.73 |
| LA Volume (cc/m2) |
44.4 |
(11.9) |
45.9 |
(11.5) |
0.56 |
| Duration of Ablation |
41.7 |
(23.4) |
34.4 |
(16.2) |
0.09 |
| Diabetes, n (%) |
5 |
(11%) |
10 |
(23%) |
0.16 |
| Coronary Artery Disease, n (%) |
7 |
(16%) |
5 |
(11%) |
0.53 |
| Chronic Kidney Disease, n (%) |
3 |
(6%) |
1 |
(2%) |
0.33 |
| Hypertension, n (%) |
27 |
(61%) |
27 |
(61%) |
1.00 |
| Congestive Heart Failure, n (%) |
5 |
(11%) |
5 |
(11%) |
1.00 |
| Chronic Obstructive Pulmonary Disease, n (%) |
3 |
(6%) |
3 |
(7%) |
0.96 |
| RV Systolic Pressure |
28.8 |
(7.9) |
28.4 |
(7.6) |
0.81 |
| Antiarrhythmic Drug Therapy, n (%) |
14 |
(30%) |
9 |
(20%) |
0.28 |
| ACE Inhibitor/ARB, n (%) |
14 |
(30%) |
12 |
(27%) |
0.74 |
| Beta Blocker, n (%) |
35 |
(74%) |
36 |
(80%) |
0.53 |
| Calcium Channel Blocker, n (%) |
11 |
(23%) |
10 |
(22%) |
0.89 |
| Statin, n (%) |
25 |
(53%) |
31 |
(69%) |
0.12 |
| Rhythm, n (%) |
|
|
|
|
0.43 |
| . Sinus |
4 |
(9%) |
2 |
(4%) |
|
| . AFib/Flutter |
43 |
(91%) |
43 |
(96%) |
|
| LV Ejection Fraction |
53.7 |
(12.5) |
53.4 |
(12.7) |
0.90 |
| LV End Diastolic Diameter |
52.0 |
(7.3) |
52.1 |
(6.6) |
0.93 |
| LV End Systolic Diameter |
36.1 |
(8.7) |
35.6 |
(7.1) |
0.78 |
| LV Volume Mass |
103.5 |
(29.8) |
94.9 |
(22.9) |
0.15 |
| Right Atrial Enlargement, n (%) |
|
|
|
|
0.89 |
| . Normal |
5 |
(11%) |
9 |
(20%) |
|
| . Mild |
11 |
(24%) |
7 |
(16%) |
|
| . Moderate |
14 |
(30%) |
11 |
(25%) |
|
| . Severe |
16 |
(35%) |
17 |
(39%) |
|
| Mitral Regurgitation, n (%) |
|
|
|
|
0.12 |
| . Normal |
29 |
(62%) |
21 |
(48%) |
|
| . Mild |
15 |
(32%) |
16 |
(36%) |
|
| . Moderate |
3 |
(6%) |
7 |
(16%) |
|
| Tricuspid Regurgitation, n (%) |
|
|
|
|
0.23 |
| . Normal |
31 |
(67%) |
25 |
(56%) |
|
| . Mild |
12 |
(26%) |
15 |
(33%) |
|
| . Moderate |
3 |
(7%) |
4 |
(9%) |
|
| . Severe |
0 |
(0%) |
1 |
(2%) |
|
